北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa
作者: Song, Qingkun1; Zhou, Xinna1; Yu, Jing2; Dong, Ningning3; Wang, Xiaoli1; Yang, Huabing1; Ren, Jun1,4; Lyerly, H. Kim4
刊名: SCIENTIFIC REPORTS
发表日期: 2015-11-25
DOI: 10.1038/srep16775
卷: 5
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: ANTHRACYCLINE-PRETREATED PATIENTS ; PHASE-II TRIAL ; LIVER METASTASES ; DRUG-THERAPY ; CAPECITABINE ; GEMCITABINE ; CYTOCHROME-P450 ; VINORELBINE ; SURVIVAL
英文摘要:

This study investigated interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherapy of docetaxel and thiotepa. Totally 153 patients were retrospectively genotyped rs8192719 (c.1294 53C >T) and rs2279343 (c.785A>G). Kaplan-Meier method and Cox Proportional Hazard Regression model were used to estimate the survival. Patients with liver metastasis had worsen prognosis, conferring a 2.26-fold high risk of progression and 1.93-fold high risk of death (p < 0.05). Both CT/TT genotype of rs8192719 (c.1294 53C >T) and AG genotype of rs2279343 (c.785A>G) prolonged survival (p < 0.05). Furthermore, among liver metastatic patients, AG genotype of rs2279343 (c.785A>G) was associated with a 47% reduced risk of death and a 6-month-longer overall survival (p < 0.05). Among non-liver metastatic patients, hazard ratios of CT/TT genotype of rs8192719 (c.1294 53C >T) were 0.45 for progression and 0.40 for death; and the corresponding survival was improved by 6 months and 16 months, respectively (p < 0.05). Genotypes of CYP2B6 had an interaction with clinical efficacy of docetaxel and thiotepa on metastatic breast cancer patients; and metastatic sites also affected clinical responses. Further therapies should take into account of chemotherapy regimen, genotypes of metabolizing enzymes and metastatic sites for the particular subpopulation.

语种: 英语
所属项目编号: 81172534 ; SPCHIN1201 ; 2013-q-04
项目资助者: Natural Science Foundation of China ; Suan G Komen for Cure Foundation ; Youth Foundation of Beijing Shijitan Hospital
WOS记录号: WOS:000365274400001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58229
Appears in Collections:北京大学临床肿瘤学院_肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Duke Univ, Dept Surg, Med Ctr, Durham, NC 27710 USA
2.Capital Med Univ, Beijing Shijitan Hosp, Beijing Key Lab Therapeut Canc Vaccines, Ctr Canc, Beijing 100038, Peoples R China
3.Peking Univ, Dept Med Oncol, Canc Hosp & Inst, Beijing 100142, Peoples R China
4.Capital Med Univ, Beijing Friendship Hosp, Dept Digest Dis, Beijing 100050, Peoples R China

Recommended Citation:
Song, Qingkun,Zhou, Xinna,Yu, Jing,et al. The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa[J]. SCIENTIFIC REPORTS,2015,5.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Song, Qingkun]'s Articles
[Zhou, Xinna]'s Articles
[Yu, Jing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Song, Qingkun]‘s Articles
[Zhou, Xinna]‘s Articles
[Yu, Jing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace